°®ÍþÄÌapp

Close

Publications

Haldane, V; Tan, YG; Teo, KW Q; Koh, JJ K; Srivastava, A; Cheng, RX; Yap, YC; Ong, P-S; Van Dam, RM; Foo, JM; Müller-Riemenschneider, F; Koh, GC-H; PEREL, P; LEGIDO-QUIGLEY, H;
2019
JMIR mHealth and uHealth, (2019).7 3
Carrillo-Larco, RM; Altez-Fernandez, C; Pacheco-Barrios, N; Bambs, C; Irazola, V; MIRANDA, JJ; Danaei, G; PEREL, P;
2019
GLOBAL HEART, (2019).14 1
Kehlenbrink, S; SMITH, J; ANSBRO, É; FUHR, DC; Cheung, A; RATNAYAKE, R; Boulle, P; Jobanputra, K; PEREL, P; ROBERTS, B;
2019
LANCET DIABETES & ENDOCRINOLOGY, (2019).7 8
Who makes the decision to receive Oxaliplatin among stage III colorectal cancer (CRC) patients?.
HASSAN, S; Miles, A; MORRIS, M;
2019
PSYCHO-ONCOLOGY, (2019).28,
GILHAM, C; Sargent, A; Kitchener, HC; PETO, J;
2019
Health Technol Assess, (2019).23 28
GILHAM, C; Sargent, A; PETO, J;
2019
BJOG : an international journal of obstetrics and gynaecology, (2019).127 1
RAKE, C; GILHAM, C; Bukasa, L; Ostler, R; Newton, M; Peto Wild, J; Aigret, B; Hill, M; Gillie, O; Nazareth, I; Sasieni, P; Martineau, A; PETO, J;
2018
Health technology assessment (Winchester, England), (2018).24 10
GILHAM, C; RAKE, C; Hodgson, J; Darnton, A; Burdett, G; Peto Wild, J; Newton, M; Nicholson, AG; Davidson, L; Shires, M; Treasure, T; PETO, J; TIPS Collaboration,;
2018
International journal of epidemiology, (2018).47 6
BENITEZ MAJANO, S; Di Girolamo, C; RACHET, B; MARINGE, C; Guren, MG; Glimelius, B; Iversen, LH; Schnell, EA; Lundqvist, K; Christensen, J; MORRIS, M; COLEMAN, MP; WALTERS, S;
2018
The Lancet Oncology, (2018).20 1
MUDIE, K; Jin, MM; Tan,; Kendall, L; Addo, J; DOS-SANTOS-SILVA, I; Quint, J; SMEETH, L; COOK, S; NITSCH, D; Natamba, B; Gomez-Olive, FX; Ako, A; PEREL, P;
2018
Journal of global health, (2018).9 2